logo-loader
Iofina PLC

Statement regarding share price rise

/**/ p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .z{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.z{}p.aq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: center}p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}p.as{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.at{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.au{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.av{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}span.aj{color:black}p.aw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify} span.ah{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.ax{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.ay{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.az{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt; text-align: justify}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;text-align:justify;line-height:normal}span.aa{color:blue} /**/
RNS Number : 8882Y
Iofina PLC
14 May 2019
 

 

14 May 2019

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Statement regarding share price rise

 

Iofina, specialists in the exploration and production of iodine and halogen-based specialty chemical derivatives, notes the recent sustained rise in its share price.

 

While the Company knows of no reason for this rise other than its recently reported positive results and the reported strengthening in the iodine market, it can confirm that it is currently in the advanced stages of an equity fundraising for at least £5m that will allow it to pay down some of its debt and progress its plans to construct IO#8. Due to the recent rise in the share price, it is likely that the fundraising will be completed at a discount to the market price per ordinary share in Iofina. The directors of the Company will consider the impact of any fundraising on shareholders when deciding whether or not to proceed.

 

The Company intends that a proportion of the funds will be raised via an Open Offer to allow existing shareholders to participate.

 

There can be no certainty however that this fundraising will proceed or on what terms.

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Matthew Radley (corporate finance)

Camille Gochez (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7544 275 882

About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

THE INFORMATION COMMUNICATED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
SPMZMGMKRFVGLZM

Quick facts: Iofina PLC

Price: £0.27

Market: LSE
Market Cap: £52.57 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

E-Therapeutics signs deal with top five global pharma company for new project

Headlines from the Proactive UK newsroom. E-therapeutics (LON:ETX) is to work with a global, top five pharmaceutical company on a project related to neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's. Results and the IP of the project will remain the property of...

1 week, 4 days ago